Non-motor symptoms in newly diagnosed Parkinson’s disease patients

El-Heneedy, Yasser Abo Elfotoh; Bahnasy, Wafik Said

doi:10.1186/s41983-019-0070-2

Cited by 12 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in line with prevalence of anxiety among patients with PD by Broen et al and Leentjens et al ranging from 24.5 to 46.7 with GAD as the most common single disorder and 31.1% having mixed anxiety disorder [34,35]. In Egypt, Ragab and colleagues report anxiety prevalence around 30% [27], while in Spain and France the prevalence was 68.7% and 51%, respectively [30,31]. On the other hand, a Chinese study found the prevalence was much lower than others around 25.8% [36].…”

Section: Discussionsupporting

confidence: 79%

“…In two recent Egyptian studies, Shalash and colleagues [26] studied non-motor symptoms in 97 PD patients using BDI-score and found depression frequency at 76.7%. On the other hand, Ragab and colleagues found the prevalence at 47.5% [27]. Across literature, several studies [7,[28][29][30][31] found the prevalence of depression in PD was ranging from 32.6 to 41%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Khedr

Abdel‐Rahman

Elserogy

et al. 2020

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Depression and anxiety are non-motor symptoms of Parkinson’s disease (PD) that are often overlooked and underrated. This study aimed to highlight the frequency and risk factors of depression and anxiety among subjects with PD. Methods Sixty-four patients with PD who were diagnosed according to United Kingdom Parkinson’s Disease Society (UKPDS) Brain Bank Criteria and 50 sex- and age-matched healthy control subjects are evaluated for depression and anxiety. PD severity and staging were assessed using Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr scale. Depression and anxiety were diagnosed using DSM-IV TR criteria and scored using Hamilton Depression and Hamilton Anxiety Rating Scales (HAM-D and HAM-A). The World Health Organization Quality of Life (WHOQOL)-BREF was used to assess impact of depression and anxiety on quality of life. Results 31.25% of patients with PD had depression while 40.6% of patients had anxiety disorder. Depression was higher in females and patients with history of depression and low socioeconomic status (SES). Anxiety was common in young patients and those who had history of anxiety. Overlap between depression and anxiety was recorded in 23.4%. Total UPDRS and Hoehn and Yahr scale accounted for 33.4% of variance for depression. Total UPDRS and earlier age of onset accounted for 39% of variance for anxiety. Advanced disease stage and severity were independent predictors for depression while disease severity and younger age of onset were the main predictors for anxiety. Depression and anxiety have a negative impact on the overall quality of life of PD patients especially on physical and psychosocial domains. Conclusion Depression and anxiety are relatively common in PD. Female gender, low SES, and history of depression were the main risk factors for developing depression. Young age and history of anxiety were risk factors for anxiety. Both had negative impact on quality of life.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Khedr

Abdel‐Rahman

Elserogy

et al. 2020

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…NMS are common in PD, ranging from 14% to 80%. 19,20 It can occur at any stage of disease, may aggravate as the disease progresses and may present before onset of motor symptoms. [19][20][21] All our patients (100%) had at least one NMS.…”

Section: Discussionmentioning

confidence: 99%

“…19,20 It can occur at any stage of disease, may aggravate as the disease progresses and may present before onset of motor symptoms. [19][20][21] All our patients (100%) had at least one NMS. Two other studies in literature also described 100% prevalence of NMS in PD.…”

Section: Discussionmentioning

confidence: 99%

Non-Motor Symptoms and their associated factors in Parkinson’s Disease

Qayyum¹,

Khan²,

Iqbal³

et al. 2021

J Islamabad Med Dental Coll

View full text Add to dashboard Cite

Aim: To find the frequency of Non Motor Symptoms in patients with Parkinson’s Disease (PD) and describe their association with different factors like age, gender and duration of disease. Methodology: A cross sectional observational study was carried out in Rehman Medical Institute, Peshawar for the period of 1year. All patients of idiopathic Parkinson’s disease (PD) were included. 13 Non motor symptoms (NMS) were evaluated and noted in predesigned proforma. Data was entered and analyzed by SPSS 22. Results: Mean Age was 62.10±10.01 years. 58.82%(n=40) were males. 47.05%(n=32) belong to urban residence. Mean duration of illness was 4.52±3.82 years. NMS were found in 100% (n=68) patients. Among NMS, sleep disturbance was the most common symptom found in 77.9% (n=53) followed by constipation that was present in 75%(n=51) of patients. Depression was significantly associated with advance age (P value 0.01) and in those taking treatment of motor symptoms of PD (P value 0.02). Perspiration was significantly more with longer duration of illness (P value 0.006) and advance age (P value 0.04). Orthostatic hypotension was associated with longer duration of disease. (P value 0.04) There was no other significant association found. Conclusion: NMS were seen in all the patients presenting to Neurology OPD in our study. The most common NMS was sleep disturbance followed by constipation and depression. Autonomic disturbance were associated with longer disease duration while depression was associated with old age.

show abstract

“…Parkinson's Disease (PD) is the most frequent cause of Parkinsonism and is estimated to affect about nine million patients by the year 2030 [1]. Patients with PD experience a broad variety of non-motor symptoms (NMSs) that manifest as cognitive, neuropsychiatric, autonomic and sensory disorders; which worsen with the disease progression and constitute main determinants of their loss of independence [2].…”

Section: Evaluation Of the Visual Pathway In Parkinson's Disease Patimentioning

confidence: 99%

Evaluation of the Visual Pathway in Parkinson’s Disease Patients

Nassar¹,

Al-Malt²,

Nawar³

et al. 2020

J Neurol Exp Neurosci

View full text Add to dashboard Cite

Objective: This study aimed to evaluate the visual evoked potentials (VEP) and optical coherence tomography (OCT) as a diagnostic biomarker in Parkinson's disease (PD) patients. Patients and Methods: Forty-seven PD patients were distributed to two groups: Group 1-included 22 newly diagnosed drug naïve PD patients. Group 2-included 25 PD patients receiving antiparkinsonian drugs. Another 20 age and sex-matched healthy subjects were recruited and served as a control group (Group 3). All participants were subjected to full medical history, general and neurological examination. All participants underwent a full neuro-ophthalmologic examination, OCT, and VEP. Results: The VEP assessment revealed that the p100 latency was significantly delayed in patients' groups in comparison to healthy subjects (p < 0.0001). Also, the p100 amplitude was significantly diminished in patients' groups in comparison to healthy subjects (p < 0.0001). These parameters showed statistically significant correlations with both disease duration and severity. There was a significant reduction in both average and quadrant Retinal Nerve Fiber Layer (RNFL) thickness (p < 0.0001) in PD patients compared to healthy subjects, with more affection of group 2. Decreased average RNFL thickness was correlated to PD duration and severity. In PD patients both delayed P100 Latency and decreased amplitude were in a statistically significant correlation with decreased average RNFL thickness. Conclusion: Our results indicate PD patients either drug naïve or medicated show functional and morphological changes in the visual pathway, these changes represent a new biomarker for follow up of PD progression.

show abstract

Non-motor symptoms in newly diagnosed Parkinson’s disease patients

Cited by 12 publications

References 43 publications

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Non-Motor Symptoms and their associated factors in Parkinson’s Disease

Evaluation of the Visual Pathway in Parkinson’s Disease Patients

Contact Info

Product

Resources

About